ArticlePloS one2021

Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?

Izabela Chmielewska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.